Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Brendon Neuen PhD

Brendon L. Neuen PhD

Senior Research Fellow, The George Institute for Global Health, Faculty of Medicine and Health, University of New South Wales, Sydney, Australia

Dr. Brendon Neuen is a Nephrologist and Director of the Kidney Trials Unit at Royal North Shore Hospital, and Senior Research Fellow at The George Institute for Global Health in Sydney, Australia. He graduated with 1st Class Honours and the Academic Medal from James Cook University, holds Masters in Global Health from the University of Oxford, PhD from the University of New South Wales. He is a Fellow of the Royal Australasian College of Physicians and the American Society of Nephrology.

He is widely recognised for his expertise in cardio-renal-metabolic medicine. Dr. Neuen established the SGLT2 Meta-Analysis Cardio-Renal Trialists' Consortium, bringing together data on >90,000 patients to better understand the effects of this class of medicines in different types of patients. His work has directly informed more than 25 major international and national guidelines, position papers and scientific statements which optimal care for people with type 2 diabetes and kidney disease.

Disclosures

Dr. Neuen has received fees for advisory boards, steering committee roles, scientific presentations, and travel support from AstraZeneca, Bayer, Boehringer and Ingelheim, Cambridge Healthcare Research, the Limbic, Medscape, and Janssen, with all honoraria paid to his institution. He serves as Secretariat of the SGLT2 Inhibitor Meta-Analysis Cardio-Renal Trialists Consortium.